Argenx discontinues late-stage Vyvgart trial in Sjögren's disease
Belgian-Dutch pharma Argenx halted a phase 3 study of efgartigimod (Vyvgart) in Sjögren's disease after the drug failed to outperform placebo, sending shares tumbling over 20%.
4 sourcesAutoimmune disease treatment
00